Human C4c quantitates human C4c in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human C4c.
Human C4c quantitates human C4c in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human C4c.
C4B may be involved in the disseminated erythematous lupus (LED). A chronic, recurrent, inflammatory and often febrile multisystemic disorder of connective tissue, characterized mainly by the involvement of skin, joints, kidneys and serosal membranes. Its etiology is unknown, but it is thought to be a failure of the mechanisms of regulation of the autoimmune system. The disease is characterized by a wide variety of system dysfunctions, high rate of erythrocyte sedimentation, and LE cell formation in the blood or bone marrow. Disease sensitivity is associated with variations affecting the gene represented in this entry. The interindividual variation in the number of copies (CNV) of the C4 complement and the associated polymorphisms result in different LED sensitivity. The risk of LED sensitivity was shown to be significantly increased in subjects with only two copies of total C4. A high number of copies is a protective factor against LED.
Sensitivity
Sensitivity of the dosage: 21 pg/ml.
Measurement range
Dose range: 21 to 5,000 pg/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Target
Target: C4c supplement.
Samples
Type of sample: Plasma, Serum, Surnatant (Serum volume, 50 µl; plasma, 50 µl; supernatant, 50 µl).
Technical specifications
General
Brand
Invitrogen
Supplier ref. (Fisher Scientific)
17114813
Specifications
Accession number
C4 acid supplement; C4 basic supplement; C3 alpha-2-macroglobulin-containing protein 2 and PzP alpha-2-macroglobulin-containing protein 3 and PzP; c4 supplement; C4A; C4a anaphylatoxin; C4B; C4B_2; C4B1; C4B12; C4B2; C4B3; C4B5; C4b-A; C4b